Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

Lannett Signs Agreement with PharmaSeed for Topical Pharma Drug

  • Lannett Company signed a research agreement with PharmaSeed Bioservices, under which PharmaSeed will formulate a certain topical pharmaceutical product, sales of which the company reports were more than $300 million in 2005.

    Currently, this product is covered by a patent, which Lannett may challenge. "This product is a large market opportunity drug, with a significant barrier to entry," mentions Arthur Bedrosian, president and CEO of Lannett.

    Lannett will submit the ANDA for this product and market the product in the U.S. The company also retains worldwide distribution rights to this product and will begin submitting applications with appropriate regulatory authorities in international markets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »